Recently published research from GlobalData, "EpiCast Report: Migraine - Epidemiology Forecast to 2023", is now available at Fast Market Research

Boston, MA -- (ReleaseWire) -- 03/13/2014 --Migraine is typically characterized by recurring headaches, throbbing pain on one side of the head along with one or more of the following symptoms: nausea; vomiting; and increased sensitivity to light, sound and smell (Bigal and Lipton, 2006). Because migraine is one of the most prevalent types of headache, there is a substantial economic and social burden associated with the condition worldwide, and it is therefore recognized as a high-priority public health problem by the World Health Organization (WHO) (Leonardi et al., 2005; Lusic, 2001). The Global Burden of Disease (GBD) study in 2010 ranks migraine as the first among the neurological disorders (Leonardi and Raggi, 2013).

In 2023, GlobalData epidemiologists forecast that the total prevalent cases of migraine in the 7MM remained almost the same, with 75.83 million total prevalent cases in 2013 and 76.38 million total prevalent cases, with an annual growth rate (AGR) of 0.07% in the forecast period. Throughout the forecast period, the US will have the highest number of total prevalent cases of migraine, with 29.61 million total prevalent cases in 2013 and 31.13 million total prevalent cases in 2023.

View Full Report Details and Table of Contents

GlobalData epidemiologists obtained total prevalence data for migraine from peer-reviewed journals and population-based studies in the respective markets and used consistent methodology to ensure comparability of results. Furthermore, GlobalData epidemiologists made a meaningful assumption that the age- and sex-specific total prevalence of migraine in the 7MM would remain constant throughout the forecast period because epidemiologic literature suggests relatively stable trends in the prevalence of migraine worldwide, thereby providing a realistic and meaningful forecast for the age- and sex-specific total prevalent cases of migraine in the 7MM.

Scope

- The Migraine EpiCast Report provides an overview of the risk factors, comorbidities, and global trends of migraine in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total prevalent cases of migraine segmented by age (beginning at 18 years and ending at 80 years and older), sex, and the number of total prevalent cases of migraine with aura and without aura in these markets.
- The migraine epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to Get This Report

- Develop business strategies by understanding the trends shaping and driving the global migraine market.
- Quantify patient populations in the global migraine market to improve product design, pricing, and launch plans.

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- EpiCast Report: Overweight and Obesity - Epidemiology Forecast to 2022
- EpiCast Report: Diabetic Foot Ulcers - Epidemiology Forecast to 2022
- EpiCast Report: Acute Coronary Syndrome (ACS) - Epidemiology Forecast to 2022
- EpiCast Report: Psoriasis - Epidemiology Forecast to 2022
- EpiCast Report: Postmenopausal Vaginal Atrophy - Epidemiology Forecast to 2022
- EpiCast Report: Dry Eye Syndrome - Epidemiology Forecast to 2022
- EpiCast Report: Gram-Negative Bacterial Urinary Tract Infection - Epidemiology Forecast to 2022
- EpiCast Report: Systemic Lupus Erythematosus Epidemiology Forecast to 2022
- EpiCast Report: Trigeminal Neuralgia - Epidemiology Forecast to 2022
- EpiCast Report: Breast Cancer - Epidemiology Forecast to 2022